PowerPoint presentation telling the story of Gavi, the Vaccine Alliance.

1. About vaccines About Gavi Healthy communities Closing the immunisation gap
www.gavi.org
Name of presenter
Place, date
1. About vaccines
2. About Gavi
3. Healthy communities
4. Closing the immunisation gap
Gavi, the
Vaccine Alliance

2. About vaccines About Gavi Healthy communities Closing the immunisation gap
About vaccines
About vaccines

3. About vaccines About Gavi Healthy communities Closing the immunisation gap
The world before vaccines
Flu pandemic
1918-1920
> 50-100 million deaths worldwide
Smallpox
epidemic
INDIA
1974
15,000 deaths
Yellow fever
PHILADELPHIA
1793
>5,000 deaths
Cholera
pandemic
EUROPE
1829-1851
>200,000 deaths
About vaccines
Polio
NEW YORK
1916
6,000 deaths
Examples of major disease outbreaks

4. About vaccines About Gavi Healthy communities Closing the immunisation gap
What is a vaccine?
Vaccines use the body’s natural defenses to safely develop immunity
About vaccines
weakened
form of
disease
antibodies
2
actual
disease
antibodies
3
1
weakened
form of
disease

5. About vaccines About Gavi Healthy communities Closing the immunisation gap
Smallpox
1798 Rabies
1885
Typhoid
1886
Cholera
1896
Plague
1897
Tuberculosis
(Bacille Calmette-Guérin)
1927 Typhus
1938
Tetanus toxoid
Pertussis
1926
Diphtheria
toxoid
1923
Influenza
1936
Yellow
Fever
1935
Polio (injected inactivated)
(1955) Mumps, live
(1967)
Anthrax, secreted proteins (1970)
Pneumococcus polysaccharides (1977)
Hepatitis B (plasma derived) (1981)
Tick-borne encephalitis (1981)
Hepatitis B surface antigen recombinant (1986)
Typhoid (salmonella Ty21a), Live (1989)
13 valent pneumococcal conjugates (2010)
Zoster, live (2006)
Rotavirus (attenuated and new reassortants (2006)
Human papillomavirus recombinant quadrivalent (2006)
Cold-Adapted Influenza (2003)
Rotavirus reassortants (1999)
Meningococcal conjugate* (group C) (1999)
Acellar pertussis, various (1996)
Hepatitis A, inactivated (1996)
Cholera, live attenuated (1994)
Typhoid (Vi) polysaccharide (1994)
Japanese encephalitis, inactivated (1992)
Polio (oral live) (1963)
Measles, live (1963)
Rubella, live (1969)
Meningococcal polysaccharides (1974)
Adenovirus (1980)
Rabies, cell culture (1980)
H. influenza type B polysaccharide (1985)
H. influenzae conjugate* (1987)
Varicella (1995)
Cholera (recombinant Toxin B) # (1993)
Cholera (WC-rBC) (1991)
Lyme OspA, protein (1998)
Pneumococcal conjugate, heptavalent* (2000)
Japanese encephalitis (Vera-cell) (2009)
Cholera (WC only) (2009)
Human papillomavirus recombinant bivalent (2009)
Meningococcal quadrivalent conjugates* (2005)
Quadrivalent influenza vaccines (2012)
Meningococcal C and Y and
Haemophilus influenza type b (2012)
Meningococcal B (2013)
Influenza vaccine (baculovirus) (2013)
Human papillomavirus, 9-valent (2014)
Enterovirus (2015)
Dengue (2015)
Cumulativenumberofvaccines
Acceleration in vaccine development
Sources: timeline as of the end of 2010: Plotkin SA, Plotkin SL. The development of vaccines: how the
past led to the future. Nature Reviews Microbiology, AOP, 2011, 1–5. 2011-2015: US Food and Drug
Administration (FDA)
About vaccines
50+
licensed
vaccines1798–2015

6. About vaccines About Gavi Healthy communities Closing the immunisation gap
Fully protecting children with vaccines
1. Bacillus Calmette Guerin (BCG) (1 dose)
2. Diphtheria (3 doses)
3. Tetanus (3 doses)
4. Pertussis (3 doses)
5. Hepatitis B (3–4 doses)
6. Hib (3 doses)
7. Pneumococcal (3 doses)
8. Polio (OPV and/or IPV, 3–4 doses)
9. Rotavirus (2–3 doses)
10. Measles (2 doses)
11. Rubella (1 dose)
12. HPV (2 doses) (adolescent girls)
Recommended for children in all countries
About vaccines

7. About vaccines About Gavi Healthy communities Closing the immunisation gap
1980
2017
Vaccines have changed our lives
Note: shows reduction in the number of reported cases. Source: WHO: Global and regional immunization profile, July 2018.
Available at: http://www.who.int/immunization/monitoring_surveillance/data/gs_gloprofile.pdf
Tetanus Diphtheria Pertussis Measles Polio
About vaccines
~90% reduction in common
vaccine-preventable
diseases

8. About vaccines About Gavi Healthy communities Closing the immunisation gap
Vaccines protect against common types of cancer
About vaccines
HPV vaccine
cervical cancer
Pentavalent vaccine
liver cancer caused by
hepatitis B

9. About vaccines About Gavi Healthy communities Closing the immunisation gap
No other health intervention touches so many lives
Worldwide, over 30 vaccine doses
are given every second
00:01
About vaccines

10. About vaccines About Gavi Healthy communities Closing the immunisation gap
10
About Gavi
About Gavi

11. About vaccines About Gavi Healthy communities Closing the immunisation gap
in lower-income
countries
by increasing
equitable use of
vaccines
and protecting
people’s health
Saving
children’s
lives
Gavi’s mission
About Gavi

12. About vaccines About Gavi Healthy communities Closing the immunisation gap
Vaccine Alliance partners
About Gavi
IMPLEMENTING
COUNTRY
GOVERNMENTS
DONOR COUNTRY
GOVERNMENTS
CIVIL SOCIETY
ORGANISATIONS
VACCINE
MANUFACTURERS
PRIVATE
SECTOR PARTNERS
RESEARCH
AGENCIES

13. About vaccines About Gavi Healthy communities Closing the immunisation gap
100%100%
72%
High-income
countries
Low-income
countries
% countries
with national
Hib vaccine
programmes
Note: Only countries with universal national programmes are included.
World Bank 2016 country classification has been applied to the whole time series.
Source: The International Vaccine Access Center (IVAC) VIMS database.
Data as of 31 December 2017.
Why Gavi was launched: creating equal access to vaccines
About Gavi
2017
High-income
countries
Low-income
countries
3%
2000

14. About vaccines About Gavi Healthy communities Closing the immunisation gap
How Gavi supports countries
About Gavi
Health system strengthening
support
Tailored technical
support
Vaccine
support
About vaccines Healthy communities Closing the immunisation gap

15. About vaccines About Gavi Healthy communities Closing the immunisation gap
Continued
support
The Gavi business model: reinventing aid
Country
Country
Country
Country
Country
Country
Pooling demand of
poorest countries
Strengthening vaccine
delivery platforms
Long-term
funding
Donor base
Co-financing
Market shaping
Shaping
markets
Supply Demand
Accelerating
access to vaccines
Sustaining
immunisation
Transition out
of support
About Gavi

16. About vaccines About Gavi Healthy communities Closing the immunisation gap
Gavi’s resource mobilisation model: a three-pronged approach
About Gavi
US$ 330m
US$
696m
US$
1,505m
$
US$ 32m
US$ 136m
2000 2010 2017
growing
donor
contributions
1
increasing
country
co-financing
3

17. About vaccines About Gavi Healthy communities Closing the immunisation gap
Accelerating access: our vaccine portfolio
About Gavi
Year of first
introduction/
use of stockpile
PNEUMO-
COCCAL
MULTIVALENT
MENINGITIS
INACTIVATED
POLIO
JAPANESE
ENCEPHALITIS
ORAL
CHOLERA
HPV
(CERVICAL
CANCER)
MEASLES-
RUBELLAMENINGITIS A
YELLOW
FEVER
HEPATITIS B
PENTAVALENT
HIB
2001 2002 2007 2008 2010 2013 2015 20172009 20142003 2004 2005 2006 2011 2012 2016 2018 2019
Gavi 1.0 Gavi 2.0 Gavi 3.0 Gavi 4.0
>400
introductions
and
campaigns
since 2000EBOLA TYPHOID
MEASLES
2ND DOSE
ROTAVIRUS

18. About vaccines About Gavi Healthy communities Closing the immunisation gap
Affordable and sustainable vaccine prices
Cost to immunise a child
with a full course of:
About Gavi
Approx.
USA price:
US$
1,100
~US$ 28
HEPATITIS B
PENTAVALENT
HIB
ROTAVIRUS
PNEUMOCOCCAL
INACTIVATED POLIO
MEASLES
RUBELLA
HPV (CERVICAL CANCER)
DTP

19. About vaccines About Gavi Healthy communities Closing the immunisation gap
0
20
40
60
80
100
Immunisationcoveragerate(%)
1980 1985 1990 1995 2000 2005 2010 2017
Immunisation coverage: closing the gap
About Gavi
.
Note: Includes DTP-containing vaccines, such as pentavalent vaccine.
Source: WHO/UNICEF Estimates of National Immunization Coverage, 2018
Expanded Programme
on Immunization takes off
Stagnating immunisation
coverage
Gavi support to world’s
poorest countries
High-income countries
Global
average
96%
85%
80%
Launch of Gavi
Post-Gavi
increase
2000-2017
21%
points
Lowest-income countries Gavi-supported countries

20. About vaccines About Gavi Healthy communities Closing the immunisation gap
Improving health systems: key ingredients
About Gavi
Integrated
service
delivery
Health
service
workforce
Health information
systems
Demand promotion
& community
engagement
Management
& coordination
Vaccine
supply chain

21. About vaccines About Gavi Healthy communities Closing the immunisation gap
Gavi catalyses new partnerships and innovation
About Gavi
Immunisation cold chainVaccine innovation Data and technology

22. About vaccines About Gavi Healthy communities Closing the immunisation gap
22
Healthy communities,
healthy economies
Healthy communities

23. About vaccines About Gavi Healthy communities Closing the immunisation gap
Vaccines: saving lives and boosting economies
Healthy communities
Reduced sickness
Improved
learning
Reduced burden
on families
Healthcare savings
Increased
productivity
Increased economic &
political stability

24. About vaccines About Gavi Healthy communities Closing the immunisation gap
Healthy communities, healthy economies: Gavi’s impact
Gavi-supported countries, 2000–2018
Healthy communities
700
million
children immunised
keep people healthy
>10
million
future deaths averted
vaccines save lives
>150
billion US$
economic benefits
generated
stronger economies
~20
countries
set to transition out of
Gavi support by 2020
sustainable future

25. About vaccines About Gavi Healthy communities Closing the immunisation gap
Pre-school
education
Community
health workers
Calculating immunisation’s return on investment
Public
infrastructure
Immunisation
3x
7x 9x 18x
(cost of illness)
48x
(full income
approach)
The Economic Benefits of Public Infrastructure Spending in Canada.
The Centre for Spatial Economics, September 2015
The rate of return to the HighScope Perry Preschool Program.
Department of Economics, University of Chicago, April 2009
Strengthening primary health care through community health workers…
Dessalegn H, Chambers R, Clinton C, Phumaphi J, Sirleaf J, Evans T, et al. 2015
Return on investment from childhood
immunizations in low- and middle-income
countries, 2011-20.
Health Affairs. 35(2):199-207. Ozawa S, Clark S,
Portnoy A, Grewal S, Brenzel L, Walker D. 2016
Healthy communities
In Gavi-supported countries, 2011–2020

26. About vaccines About Gavi Healthy communities Closing the immunisation gap
26
Closing the immunisation gap
Closing the immunisation gap

27. About vaccines About Gavi Healthy communities Closing the immunisation gap
The immunisation gap
19.9
million
are not fully
protected with
basic vaccines
~140
million
children born
every year
~80%
are in Gavi-supported
countries
Nigeria
India
Pakistan
Indonesia
Other Gavi
Rest of
world
Number of children globally not receiving the third dose of DTP-containing vaccine in 2017.
Sources: WHO/UNICEF Estimates of National Immunization Coverage and UNPD, 2018
Closing the immunisation gap
1 in 5 children
in Gavi-supported
countries do not get
a full course of
basic vaccines

28. About vaccines About Gavi Healthy communities Closing the immunisation gap
Increase domestic
resources for immunisation
Improve data quality
Optimise supply chains
Strengthen country leadership
Shape markets
Accelerate vaccines
Gavi’s strategy for closing the gap
Closing the immunisation gap
STRATEGIC GOALS
FOCUS AREAS: EXAMPLES
Strengthen immunisation delivery
Improve sustainability
Focus on
vaccine coverage and
overcoming inequity to
reach every child

29. About vaccines About Gavi Healthy communities Closing the immunisation gap
2000–2020: ever accelerating impact
Future deaths
prevented
Closing the immunisation gap
1 million
+4
million
+3
million
+5-6
million
13-14
million
90 million
+280
million
+200
million
+300
million
~900
million
Children
immunised
2001-
2005
2006-
2010
2011-
2015
2016-
2020
Gavi’s strategic periods
2001-
2005
2006-
2010
2011-
2015
2016-
2020
Sources: Gavi strategic demand forecasts 9 and 10,
Investing together for a healthy future: the 2016–2020 investment opportunity

30. About vaccines About Gavi Healthy communities Closing the immunisation gap
www.gavi.org
Thank you